Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2024

Open Access 06-02-2024 | Cytostatic Therapy | Pancreatic Tumors

Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma

Authors: Alessandro Fogliati, MD, Andrea Zironda, MD, Guido Fiorentini, MD, Stella Adjei, MD, Abdelrahman Amro, MBBS, Patrick P. Starlinger, MD, PhD, Travis E. Grotz, MD, Susanne G. Warner, MD, Rory L. Smoot, MD, Cornelius A. Thiels, MD, Michael L. Kendrick, MD, Sean P. Cleary, MD, Mark J. Truty, MD, MSc

Published in: Annals of Surgical Oncology | Issue 4/2024

Login to get access

Abstract

Background

The management of invasive intraductal papillary mucinous cystic neoplasm (I-IPMN) does not differ from de novo pancreatic ductal adenocarcinoma (PDAC); however, I-IPMNs are debated to have better prognosis. Despite being managed similarly to PDAC, no data are available on the response of I-IPMN to neoadjuvant chemotherapy.

Methods

All patients undergoing pancreatic resection for a pancreatic adenocarcinoma from 2011 to 2022 were included. The PDAC and I-IPMN cohorts were compared to evaluate response to neoadjuvant therapy (NAT) and overall survival (OS).

Results

This study included 1052 PDAC patients and 105 I-IPMN patients. NAT was performed in 25% of I-IPMN patients and 65% of PDAC patients. I-IPMN showed a similar pattern of pathological response to NAT compared with PDAC (p = 0.231). Furthermore, positron emission tomography (PET) response (71% vs. 61%; p = 0.447), CA19.9 normalization (85% vs. 76%, p = 0.290), and radiological response (32% vs. 37%, p = 0.628) were comparable between I-IPMN and PDAC. A significantly higher OS and disease-free survival (DFS) of I-IPMN was denoted by Kaplan–Meier analysis, with a p-value of < 0.001 in both plots. In a multivariate analysis, I-IPMN histology was independently associated with lower risk of recurrence and death.

Conclusions

I-IPMN patients have a longer OS and DFS after surgical treatment when compared with PDAC patients. The more favorable oncologic outcome of I-IPMNs does not seem to be related to early detection, as I-IPMN histological subclass is independently associated with a lower risk of disease recurrence. Moreover, neoadjuvant effect on I-IPMN was non-inferior to PDAC in terms of pathological, CA19.9, PET, and radiological response and thus can be considered in selected patients.
Appendix
Available only for authorised users
Literature
1.
Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016;14(4):585–93.CrossRefPubMed
2.
Crippa S, Capurso G, Camma C, Fave GD, Castillo CF, Falconi M. Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: a systematic review and meta-analysis. Dig Liver Dis. 2016;48(5):473–9.CrossRefPubMed
3.
Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRefPubMed
4.
Crippa S, Fogliati A, Valente R, et al. A tug-of-war in intraductal papillary mucinous neoplasms management: comparison between 2017 International and 2018 European guidelines. Dig Liver Dis. 2021;53(8):998–1003.CrossRefPubMed
5.
European Study Group on Cystic Tumours of the P. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804.CrossRef
6.
Koh YX, Chok AY, Zheng HL, Tan CS, Goh BK. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21(8):2782–800.CrossRefPubMed
7.
Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116(14):3369–77.CrossRefPubMed
8.
Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56-68.CrossRefPubMed
9.
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.CrossRefPubMed
10.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
11.
Washington MK, Berlin J, Branton PA, et al. Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts. Arch Pathol Lab Med. 2010;134(4):e19-24.CrossRefPubMed
12.
13.
Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts general hospital. Surgery. 2012;152(3 Suppl 1):S4-12.CrossRefPubMed
14.
Ciprani D, Weniger M, Qadan M, et al. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020;20(6):1213–7.CrossRefPubMed
15.
Malczak P, Sierzega M, Stefura T, et al. Arterial resections in pancreatic cancer–systematic review and meta-analysis. HPB (Oxford). 2020;22(7):961–8.CrossRefPubMed
16.
Duconseil P, Perinel J, Autret A, et al. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: should these two different diseases receive the same treatment? A matched comparison study of the French surgical association (AFC). Eur J Surg Oncol. 2017;43(9):1704–10.CrossRefPubMed
17.
Marchegiani G, Andrianello S, Dal Borgo C, et al. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. HPB (Oxford). 2019;21(5):596–603.CrossRefPubMed
18.
Mungo B, Croce C, Oba A, et al. Controversial role of adjuvant therapy in node-negative invasive intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2021;28(3):1533–42.CrossRefPubMed
19.
Rodrigues C, Hank T, Qadan M, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020;20(4):722–8.CrossRefPubMed
20.
van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9.CrossRefPubMed
21.
Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.CrossRefPubMed
22.
Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251(3):470–6.CrossRefPubMed
Metadata
Title
Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma
Authors
Alessandro Fogliati, MD
Andrea Zironda, MD
Guido Fiorentini, MD
Stella Adjei, MD
Abdelrahman Amro, MBBS
Patrick P. Starlinger, MD, PhD
Travis E. Grotz, MD
Susanne G. Warner, MD
Rory L. Smoot, MD
Cornelius A. Thiels, MD
Michael L. Kendrick, MD
Sean P. Cleary, MD
Mark J. Truty, MD, MSc
Publication date
06-02-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14875-5

Other articles of this Issue 4/2024

Annals of Surgical Oncology 4/2024 Go to the issue

Pancreatic Tumors

Centralized Care of the Surgical Oncology Patient: A Simple Task with Complex Solutions

ASO Author Reflections

ASO Author Reflections: Perioperative Lymphopenia Following Hepatectomy for Hepatocellular Carcinoma: A Routine Yet Overlooked Prognostic Biomarker

Peritoneal Surface Malignancy

Reply to Letter to the Editor Concerning “Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA”

ASO Visual Abstract

ASO Visual Abstract: Double Negativity of MRI-Detected and Pathologically Diagnosed Extramural Venous Invasion is a Favorable Prognostic Factor for Rectal Cancer

Pancreatic Tumors

Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer

ASO Author Reflections

ASO Author Reflections: Minimally Invasive Approach and Oncologic Benefit in Intrahepatic Cholangiocarcinoma (iCCA) With Risk of Very Early Recurrence: Is it Time to Consider Technique as a Key Element of Onco-Surgical Strategy?